Skin Neoplasms
Welcome,         Profile    Billing    Logout  
 42 Companies   55 Products   55 Products   61 Mechanisms of Action   3 Trials   315 News 


1234567»
  • ||||||||||  Trial completion date, Trial suspension, Trial primary completion date:  Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) -  Mar 7, 2019   
    P=N/A,  N=90, Suspended, 
    Active, not recruiting --> Completed Trial completion date: Jun 2019 --> Dec 2019 | Recruiting --> Suspended | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Potential Research Study Participant Registry (clinicaltrials.gov) -  Feb 16, 2019   
    P=N/A,  N=265, Completed, 
    Trial completion date: Jun 2019 --> Dec 2019 | Recruiting --> Suspended | Trial primary completion date: Dec 2018 --> Dec 2019 Recruiting --> Completed | N=200 --> 265 | Trial completion date: Jan 2025 --> Sep 2018 | Trial primary completion date: Jan 2025 --> Sep 2018
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Reducing Skin Cancer Risk in Childhood Cancer Survivors (clinicaltrials.gov) -  Jun 20, 2018   
    P=N/A,  N=726, Completed, 
    N=15 --> 29 Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Jan 2018 | Trial primary completion date: Apr 2018 --> Jan 2018
  • ||||||||||  Trial completion date, Trial primary completion date:  Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) -  Jun 1, 2018   
    P=N/A,  N=90, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Jan 2018 | Trial primary completion date: Apr 2018 --> Jan 2018 Trial completion date: Dec 2017 --> Jun 2019 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial completion, Trial primary completion date, Combination therapy, Metastases:  Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jan 17, 2018   
    P1,  N=96, Completed, 
    Phase classification: P1 --> P=N/A Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Sep 2009
  • ||||||||||  Samcyprone (diphenylcyclopropenone) / Phio Pharma
    Trial completion, Enrollment change, IO biomarker, Immunomodulating:  Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) -  Nov 29, 2017   
    P1,  N=6, Completed, 
    Trial primary completion date: Dec 2016 --> Apr 2015 Active, not recruiting --> Completed | N=13 --> 6
  • ||||||||||  Trial completion, Enrollment change:  A Study of Ultrasonography With Elastography in Skin Neoplasms (clinicaltrials.gov) -  Nov 7, 2017   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed | N=13 --> 6 Recruiting --> Completed | N=100 --> 30
  • ||||||||||  Enrollment closed:  Reducing Skin Cancer Risk in Childhood Cancer Survivors (clinicaltrials.gov) -  Oct 18, 2017   
    P=N/A,  N=726, Active, not recruiting, 
    Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Samcyprone (diphenylcyclopropenone) / Phio Pharma
    Trial primary completion date, IO biomarker, Immunomodulating:  Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (clinicaltrials.gov) -  Sep 11, 2017   
    P1,  N=13, Active, not recruiting, 
    Enrolling by invitation --> Active, not recruiting Trial primary completion date: Oct 2017 --> Jun 2015
  • ||||||||||  Trial initiation date, Trial primary completion date, Metastases:  Drosophila-generated CTL (clinicaltrials.gov) -  Aug 1, 2017   
    P2,  N=3, Terminated, 
    Trial primary completion date: Oct 2017 --> Jun 2015 Initiation date: Dec 2010 --> Apr 2011 | Trial primary completion date: Apr 2012 --> Dec 2011
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date, Surgery:  Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery (clinicaltrials.gov) -  Jul 6, 2017   
    P=N/A,  N=0, Withdrawn, 
    Trial primary completion date: Dec 2017 --> Jul 2016 N=230 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2015 --> Jun 2017
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Optical Imaging of Skin Cancers for Margin Delineation of Non-Melanoma Skin Cancers (clinicaltrials.gov) -  Jun 28, 2017   
    P=N/A,  N=23, Completed, 
    N=230 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2015 --> Jun 2017 Active, not recruiting --> Completed | N=55 --> 23 | Trial primary completion date: Jan 2019 --> Jun 2017
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial primary completion date, Combination therapy, Metastases:  Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Mar 22, 2017   
    P1,  N=96, Active, not recruiting, 
    Active, not recruiting --> Terminated; Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued. Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Trial initiation date, Trial primary completion date:  Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) -  Feb 17, 2017   
    P=N/A,  N=90, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016 Initiation date: Nov 2013 --> Feb 2017 | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Trial termination:  Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer (clinicaltrials.gov) -  Jan 4, 2017   
    P0,  N=18, Terminated, 
    Active, not recruiting --> Completed Completed --> Terminated; Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    Trial completion, Phase classification, Enrollment change, Trial primary completion date, Combination therapy:  MEL53: Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma (clinicaltrials.gov) -  Dec 16, 2016   
    P1,  N=4, Completed, 
    Completed --> Terminated; Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous. Suspended --> Completed | Phase classification: PN/A --> P1 | N=24 --> 4 | Trial primary completion date: Jan 2015 --> Jun 2012
  • ||||||||||  Trial completion, Trial primary completion date:  PennSCAPE: Melanoma Risk Assessment & Tailored Intervention (clinicaltrials.gov) -  Aug 19, 2016   
    P=N/A,  N=323, Completed, 
    Trial primary completion date: Jun 2016 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2011 --> Feb 2016
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date:  Sunbit UV Measuring Device to Track Sun Behavior (clinicaltrials.gov) -  Jul 19, 2016   
    P=N/A,  N=10, Terminated, 
    Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 N=20 --> 10 | Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Mar 2016; Company dissolved, no study devices available anymore
  • ||||||||||  Enrollment closed, Trial primary completion date:  New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) (clinicaltrials.gov) -  Jul 14, 2016   
    P=N/A,  N=277, Active, not recruiting, 
    N=20 --> 10 | Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Mar 2016; Company dissolved, no study devices available anymore Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Jun 2017